Pharma
OpinionBY
- By embedding children’s needs more explicitly within regulatory decision-making, we can ensure that medicines proven safe and effective in comparable jurisdictions can reach Canada’s kids faster.
OpinionBY
- By embedding children’s needs more explicitly within regulatory decision-making, we can ensure that medicines proven safe and effective in comparable jurisdictions can reach Canada’s kids faster.
- Seven provinces and two territories don’t yet have deals even though Prime Minister Mark Carney said last fall that his government is committed to
- Seven provinces and two territories don’t yet have deals even though Prime Minister Mark Carney said last fall that his government is committed to
- Seven provinces and two territories don’t yet have deals even though Prime Minister Mark Carney said last fall that his government is committed to
- Only British Columbia, Manitoba, Prince Edward Island, and the Yukon have reached pharmacare deals with the federal government, covering contraception and diabetes medications.
- Only British Columbia, Manitoba, Prince Edward Island, and the Yukon have reached pharmacare deals with the federal government, covering contraception and diabetes medications.
- Only British Columbia, Manitoba, Prince Edward Island, and the Yukon have reached pharmacare deals with the federal government, covering contraception and diabetes medications.
- The agency’s 2024-25 departmental results report uses rates from a 2021 survey. Newer data is available, but that source doesn’t include rates from all
- The agency’s 2024-25 departmental results report uses rates from a 2021 survey. Newer data is available, but that source doesn’t include rates from all
- The agency’s 2024-25 departmental results report uses rates from a 2021 survey. Newer data is available, but that source doesn’t include rates from all
- But that doesn’t mean the drug pricing tribunal can’t look at past years’ data to inform future reviews of drug prices, says director general
- But that doesn’t mean the drug pricing tribunal can’t look at past years’ data to inform future reviews of drug prices, says director general
- But that doesn’t mean the drug pricing tribunal can’t look at past years’ data to inform future reviews of drug prices, says director general
- Interim NDP leader Don Davies says the feds must continue negotiating deals with provinces and territories under the pharmacare law passed last year.
- Interim NDP leader Don Davies says the feds must continue negotiating deals with provinces and territories under the pharmacare law passed last year.
- Interim NDP leader Don Davies says the feds must continue negotiating deals with provinces and territories under the pharmacare law passed last year.
- Pharmacare and Bill C-234, an act to amend the Greenhouse Gas Pollution Pricing Act, are likely to be top issues for government relations this
- Pharmacare and Bill C-234, an act to amend the Greenhouse Gas Pollution Pricing Act, are likely to be top issues for government relations this
- Pharmacare and Bill C-234, an act to amend the Greenhouse Gas Pollution Pricing Act, are likely to be top issues for government relations this
- A public pharmacare program that provides coverage for all Canadians, regardless of age, occupation, or income, would alleviate financial burdens and allow people to
- A public pharmacare program that provides coverage for all Canadians, regardless of age, occupation, or income, would alleviate financial burdens and allow people to
- A public pharmacare program that provides coverage for all Canadians, regardless of age, occupation, or income, would alleviate financial burdens and allow people to
- If we want politicians to know what’s important, we need to make sure that they hear answers to questions that get at the heart
- If we want politicians to know what’s important, we need to make sure that they hear answers to questions that get at the heart
- If we want politicians to know what’s important, we need to make sure that they hear answers to questions that get at the heart
- Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need
- Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need
- Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need
- Private insurers want Canada to embrace a multi-payer pharmacare system without the tools necessary to protect public interests, promote equity, and ensure value.
- Private insurers want Canada to embrace a multi-payer pharmacare system without the tools necessary to protect public interests, promote equity, and ensure value.
- Private insurers want Canada to embrace a multi-payer pharmacare system without the tools necessary to protect public interests, promote equity, and ensure value.
